INCYBiopharmaceuticals
Incyte
- Price
- $114.63
- Discount category
- Far above intrinsic value
- Analysts
- Leaning bullish
- Next earnings
- Feb 9 · · estimated
- Pick status
- Research only
In short
- Thesis
- Investors pay a premium for the fast growth of Opzelura and blood cancer drugs at Incyte, and only positive Phase 3 data and approvals through 2027 that replace Jakafi after 2028 can earn this price.
- Gap
- Can close. The Phase 3 data in Q4 2026 and the US decision on povorcitinib in Q1 2027 show how fast new sales can replace Jakafi, whose patents expire in 2028.
Company guidance: 2026 net sales $5,210 to $5,300 million; Jakafi $3,220 to $3,270 million; Opzelura $1,100 to $1,120 million (, Q3 2026 results release (8-K))
Price history
About
Incyte Corporation (Incyte) is a drug company based in Wilmington, Delaware. Its largest product is Jakafi (ruxolitinib), a treatment for myelofibrosis and other blood diseases. It also sells Opzelura (ruxolitinib cream) for skin diseases and a group of blood cancer products, such as Monjuvi, Niktimvo, Pemazyre and Iclusig.
It earns royalties on products that partners sell, such as Olumiant and Jakavi. Net sales were $1,316 million in Q3 2026 and $3,909 million for nine months. Jakafi made $827 million of the Q3 sales.
Bill Meury is Chief Executive Officer. The common stock trades on Nasdaq in US dollars. Incyte files 10-K and 10-Q reports.
Thesis
The price of Incyte depends on how fast new products and pipeline drugs can replace Jakafi, whose patents expire in mid and late 2028. Jakafi made about 63% of net sales in Q3 2026 and grew only 4%. Opzelura grew 36% and Hematology and Oncology products grew 38%. Incyte bought Vega Therapeutics in July 2026 for $1.25 billion and booked a one-time $1.23 billion expense for it.
For the price to hold or rise, four things must be true. Opzelura and the blood cancer products must keep growing at a fast rate. Povorcitinib must win approval in hidradenitis suppurativa in 2027 and show good Phase 3 data in prurigo nodularis. The mutCALR antibody INCA033989 and the KRAS G12D inhibitor must keep their early results in later trials.
Spending on research must not rise faster than sales. Phase 3 data for povorcitinib and ruxolitinib cream are due in Q4 2026. A US decision on povorcitinib is expected in Q1 2027. If these fail, the loss of Jakafi sales after 2028 will be hard to replace.
Checkpoints
- Q4 2026 · est.Due this quarterPhase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativaBoth studies meet their main goals, and this passes; a miss in either study fails.
- Feb 9, 2027 · est.PendingQ4 2026 results and 2027 guidanceNet sales for 2026 are in the raised range of $5,210 million to $5,300 million and the 2027 guidance shows growth outside Jakafi, and this passes; a miss or weak guidance fails.
- Q1 2027 · est.PendingUS decision on povorcitinib in hidradenitis suppurativaThe FDA approves povorcitinib and Incyte launches it in Q1 2027, and this passes; a delay or a refusal fails.
Recent events
- November 13, 2026Incyte decided not to start MAESTRA-3, a planned Phase 3 study of INCB123667, its CDK2 inhibitor, with bevacizumab as first-line maintenance therapy in ovarian cancer. The study was to start in Q4 2026. Incyte said that the decision comes from the priorities of its development portfolio, not from safety or efficacy data, and that it does not change its financial guidance or its long-term outlook.
- October 29, 2026Incyte reported Q3 2026 results. Total revenue rose 14% to $1.56 billion, and net sales rose 14% to $1.32 billion. It raised its 2026 net sales guidance to $5,210 million to $5,300 million. The release also said that the CHMP gave a positive opinion on povorcitinib in September, and that Incyte agreed with the US Centers for Medicare & Medicaid Services in August on Jakafi pricing for state Medicaid programs.
- October 29, 2026Incyte filed its Form 10-Q for Q3 2026. It showed an acquired in-process research and development expense of $1,231.5 million for Vega. A loss of $784.8 million for the quarter followed. Cash, cash equivalents and marketable securities were $3.9 billion.
Show 1 older eventHide older events
- July 6, 2026Incyte completed its purchase of Vega Therapeutics for $1.25 billion in cash. Vega owns latarcibart, an anti-Protein S antibody in Phase 3 for von Willebrand disease. The seller can get up to $750 million more if sales reach milestones.
Latest news and filings
- Last earnings
- October 29, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 9, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed incy-20260930
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KOther company newsFiled incy-20260831
- 10-QQuarterly report for the period ended Jun 30, 2026Filed incy-20260630
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KOther company newsFiled incy-20260706
- 8-KOther company newsFiled incy-20260622
- 8-KShareholder vote resultsFiled incy-20260608
- 8-KOther company newsFiled incy-20260608
- 10-QQuarterly report for the period ended Mar 31, 2026Filed incy-20260331
Risks
Bull case: Opzelura grew 36% and Hematology and Oncology products grew 38% in Q3 2026, and povorcitinib can add a new product with a US decision expected in Q1 2027.
- Jakafi loses patent protection in 2028. The patents on ruxolitinib expire in mid and late 2028. Jakafi made $827 million of Q3 2026 net sales, and generic drugs can cut this sales line quickly.
- Trials can fail. Incyte spends heavily on Phase 3 trials, and R&D expenses were $2,824.5 million in nine months with the Vega charge. A failed trial costs both money and time.
- Prices can fall. Incyte signed a pricing agreement for state Medicaid programs, and it says that it expects to avoid some future federal pricing models. Other pricing rules can still reduce sales.
- Opzelura faces generic challenges. Four makers of generic drugs sent Incyte notice letters about Opzelura, and the case outcomes can change its long-term sales.
- Milestones can add cost. Incyte may owe up to $750 million to the seller of Vega if sales of latarcibart reach set levels.
Key statistics
- Market cap
- $23B
- Shares of Oct 22, 2026
- P/E (trailing)
- 58.5
- Price of Nov 20, 2026
- EPS (trailing)
- $1.96
- 12 months to Sep 30, 2026
- 52-week range
- $89.25 – $132.60
- To Nov 12, 2026
- Beta
- 0.78
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 1.6M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $3.9B
- Debt
- $0.0M
- Net cash
- $3.9B
Cash against debt
debt covered by cash
At September 30, 2026, Incyte had cash and cash equivalents of $3,275.9 million and marketable securities of $578.7 million, which is $3,854.6 million in all. Interest expense was only $1.8 million for nine months, and Incyte has no borrowings. Incyte paid $1.25 billion in cash for Vega in July 2026. It may owe up to $750 million more on sales milestones. Incyte recorded the Vega purchase as an in-process R&D expense of $1,231.5 million in Q3 2026.
Dividends
Incyte does not pay a dividend.
Source: company filings and market data, read on November 13, 2026.
Questions about Incyte
What does Incyte do?
Incyte Corporation (Incyte) is a drug company based in Wilmington, Delaware. Its largest product is Jakafi (ruxolitinib), a treatment for myelofibrosis and other blood diseases. Its market cap is $23B at the current price of $114.63.
When does Incyte report earnings next?
This is an estimate: Incyte may report on February 9, 2027. It last reported results on October 29, 2026.
Is Incyte stock below its intrinsic value?
Incyte stock is far above intrinsic value. This is general information, not advice.
What changed recently at Incyte?
The latest update is from November 13, 2026. Incyte decided not to start MAESTRA-3, a planned Phase 3 study of INCB123667, its CDK2 inhibitor, with bevacizumab as first-line maintenance therapy in ovarian cancer.
What are the main risks for Incyte?
Jakafi loses patent protection in 2028. Trials can fail. Prices can fall.
How much debt and cash does Incyte have?
At September 30, 2026, Incyte had $0.0M of debt and $3.9B of cash.
Does Incyte pay a dividend?
No. Incyte does not pay a dividend.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| INCYIncyte | 58.5x | n/a | n/a | 29.1x |
| RPRXRoyalty Pharma | 44.7x | n/a | n/a | n/a |
| JAZZJazz Pharmaceuticals | 68.1x | n/a | 8.8% | 20.0x |
| APPAppLovin | 23.5x | n/a | n/a | n/a |
| PCGPG&E | 10.2x | n/a | -8.3% | 17.0x |
| Peer median | 34.1x | n/a | 0.2% | n/a |
- INCY trades at 58.5x earnings, 72% above the peer median of 34.1x.
- Against its own history, the P/E is 101% above its average of 29.1x over 5 profitable years.
The peers are the companies on this site most like INCY. The multiples come from company filings and today's price, and P/E uses GAAP diluted EPS. Picks shows no analyst forecast: the only look ahead is a company's own EPS guidance, where it gives one. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- JAZZJazz PharmaceuticalsShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- UNHUnitedHealth GroupShares: Regulation and courts
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- APPAppLovinShares: Regulation and courts
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- PCGPG&EShares: Regulation and courts
- Intrinsic value
- Far below intrinsic value
- Gap
- Will probably not close
- BTIBritish American TobaccoShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Will probably not close
Loading your notes…
Read it all? Star INCY or pass, then go on to the next one.